All In Biotech

Drug Trial Radar · NCT05292495

A Trial of HR17031 Injection With Renal Insufficiency

A Single-dose, Open Design Study to Evaluate The Pharmacokinetics of HR17031 Injection With Renal Insufficiency

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 12, 2022

Primary completion

Apr 10, 2024

Study completion Apr 10, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild, moderate and severe renal insufficiency and end-stage renal disease and subjects with normal renal function.

Conditions

  • Improved Glycemic Control in Patients With Type 2 Diabetes

Interventions

  • HR17031 injectionDrug

    HR17031 injection; administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics parameters of INS068 and SHR20004: CmaxTime frame: Based on pre-dose, 2-96 hours post-dose sampling times
  2. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-tTime frame: Based on pre-dose, 2-96 hours post-dose sampling times
  3. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-infTime frame: Based on pre-dose, 2-96 hours post-dose sampling times

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.